Carnosine Did Not Affect Vascular and Metabolic Outcomes in Patients with Prediabetes and Type 2 Diabetes: A 14-Week Randomized Controlled Trial.

Saadati S, Cameron J, Menon K, Hodge A, Lu ZX, de Courten M, Feehan J, de Courten B

Nutrients19 Nov 2023Cited by 12 (Europe PMC)

PMID38004228PMCIDPMC10674211DOI10.3390/nu15224835PepBankPUB-38004228

Summary

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with prediabetes and type 2 diabetes mellitus (T2DM). Carnosine has been suggested as a potential approach to reduce ASCVD risk factors. However, there is a paucity of human data. Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM. In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo. We evaluated endothelial dysfunction, arterial stiffness, lipid parameters, blood pressure, heart rate, hepatic and renal outcomes before and after the intervention. Carnosine supplementation had no effect on heart rate, peripheral and central blood pressure, endothelial function (logarithm of reactive hyperemia (LnRHI)), arterial stiffness (carotid femoral pulse wave velocity (CF PWV)), lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo. In conclusion, carnosine supplementation did not improve cardiovascular and cardiometabolic risk factors in adults with prediabetes and T2DM with good glycemic control. Therefore, it is improbable that carnosine supplementation would be a viable approach to mitigating the ASCVD risk in these populations. The trial was registered at clinicaltrials.gov (NCT02917928).

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on heart rate versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on heart rate versus placebo.
Peptide
L-carnosine
Outcome
No significant changeHeart rate
Study
n = 49
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Carnosine supplementation had no effect on heart rate,
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422801
02HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on peripheral blood pressure versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on peripheral blood pressure versus placebo.
Peptide
L-carnosine
Outcome
No significant changePeripheral blood pressure
Study
n = 49
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Carnosine supplementation had no effect on heart rate, peripheral and central blood pressure,
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422802
03HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on central blood pressure versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on central blood pressure versus placebo.
Peptide
L-carnosine
Outcome
No significant changeCentral blood pressure
Study
n = 49
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Carnosine supplementation had no effect on heart rate, peripheral and central blood pressure,
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422803
04HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on endothelial function versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on blood vessel lining function versus placebo.
Peptide
L-carnosine
Outcome
No significant changeEndothelial function (LnRHI)
Study
n = 49
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Carnosine supplementation had no effect on heart rate, peripheral and central blood pressure, endothelial function (logarithm of reactive hyperemia (LnRHI)),
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422804
05HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on arterial stiffness versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on artery stiffness versus placebo.
Peptide
L-carnosine
Outcome
No significant changeArterial stiffness (CF PWV)
Study
n = 49
Comparator
Placebo
Outcome group
Vascular function · Cardiovascular
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Carnosine supplementation had no effect on heart rate, peripheral and central blood pressure, endothelial function (logarithm of reactive hyperemia (LnRHI)), arterial stiffness (carotid femoral pulse wave velocity (CF PWV)),
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422805
06HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on lipid parameters versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on blood lipid measures versus placebo.
Peptide
L-carnosine
Outcome
No significant changeLipid parameters
Study
n = 49
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422806
07HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on liver fibroscan indicators versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on liver fibroscan indicators versus placebo.
Peptide
L-carnosine
Outcome
No significant changeLiver fibroscan indicators
Study
n = 49
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422807
08HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on liver transient elastography versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on liver stiffness measurements versus placebo.
Peptide
L-carnosine
Outcome
No significant changeLiver transient elastography
Study
n = 49
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422808
09HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on liver function tests versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on liver function tests versus placebo.
Peptide
L-carnosine
Outcome
No significant changeLiver function tests
Study
n = 49
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422809
10HumanRandomized controlled trialEfficacy outcome
In patients with well-controlled prediabetes or T2DM, carnosine had no effect on renal outcomes versus placebo.
In plain wordsIn patients with well-controlled prediabetes or T2DM, carnosine had no effect on kidney outcomes versus placebo.
Peptide
L-carnosine
Outcome
No significant changeRenal outcomes
Study
n = 49
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM.
Summary · context
In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo.
Show in the study text Report a problemFND-3800422810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT02917928

The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health

Monash Universityn = 40Oct 2016 to est. Jul 2023

Poor Glycemic Control · Cardiovascular Risk Factors · Cognitive Function 1, Social

Trial page ClinicalTrials.govUpdated 28 Jun 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.